Duke Heart Failure Symposium: Leading Edge of Medical Management
This is a virtual, live event. The overall purpose of this event is to discuss advances in heart failure care to enhance learners’ knowledge and competency to incorporate evidence-based updates in clinical practice. Heart failure is a rapidly growing clinical problem in the United States and worldwide. Heart failure is the most common discharge diagnosis among patients 65 and older in the United States. Epidemiologic projections suggest that the overall burden of heart failure care will continue to grow dramatically, with an expected increase in prevalence of 46% from 2012 to 2030, resulting in over 8 million adults living with heart failure (1,2). Heart failure is estimated to account for over 30 billion dollars per year of health care spending, and controlling costs and improving care of heart failure patients has been a major focus of health care reform in the United States. Heart failure care includes appreciation for the genetic risk factors and social determinants of health as they differentially impact disease burden and risk for progression (3) Advanced forms of heart failure carry a mortality rate greater than that of most cancers. Thus, it is critically important to raise awareness and improve knowledge about the symptoms, diagnosis, newer therapeutic options and outcomes in heart failure. A variety of recent developments in the field of heart failure therapies, including novel drugs, new devices, and care innovations inform the current effort to improve heart failure education and refine approaches to disease management for clinicians (4). Physicians and other practitioners must be armed with the most up-to-date evidence to guide best treatments and improve the prognosis for patients with heart failure.
- Discuss the role of new emerging drug therapy for chronic heart failure with reduced ejection fraction and evolving treatment paradigms for instituting and titrating all drug classes.
- Define an optimal pathway to achieve optimal therapy
- Identify the role of clinical trials in the development of new heart failure therapies: goals of current and future trial design and endpoints
- 3.75 AMA PRA Category 1 Credit(s)™
- 3.75 ANCC
- 3.75 Attendance
- 3.75 JA Credit - AH
- 3.75 Approved for AMA PRA Category 1 Credit(s)™